These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 31190000

  • 1. Implementation of the 2018 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort.
    Zare S, Rong J, Daehne S, Roma A, Hasteh F, Dell'Aquila M, Fadare O.
    Mod Pathol; 2019 Nov; 32(11):1566-1573. PubMed ID: 31190000
    [Abstract] [Full Text] [Related]

  • 2. Impact of 2013 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2 Fluorescent In Situ Hybridization Testing in Breast Cancers : Experience From a National Reference Laboratory.
    Gulbahce HE.
    Am J Clin Pathol; 2017 Oct 01; 148(4):308-313. PubMed ID: 28967951
    [Abstract] [Full Text] [Related]

  • 3. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K, Tantravahi U, Lomme MM, Pasquariello T, Steinhoff M, Sung CJ.
    Breast Cancer Res Treat; 2016 Jun 01; 157(3):405-11. PubMed ID: 27180259
    [Abstract] [Full Text] [Related]

  • 4. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW, Lee K, Chung YR, Jang MH, Ahn S, Park SY.
    Hum Pathol; 2020 Apr 01; 98():10-21. PubMed ID: 32027910
    [Abstract] [Full Text] [Related]

  • 5. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH, Lim AS, Thike AA, Tien SL, Tan PH.
    Arch Pathol Lab Med; 2016 Feb 01; 140(2):140-7. PubMed ID: 26910218
    [Abstract] [Full Text] [Related]

  • 6. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Donaldson AR, Shetty S, Wang Z, Rivera CL, Portier BP, Budd GT, Downs-Kelly E, Lanigan CP, Calhoun BC.
    Cancer; 2017 Jun 15; 123(12):2230-2239. PubMed ID: 28192599
    [Abstract] [Full Text] [Related]

  • 7. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio <2.0 and Average HER2 Copy Number ≥4.0 and <6.0.
    Hoda RS, Brogi E, Xu J, Ventura K, Ross DS, Dang C, Robson M, Norton L, Morrow M, Wen HY.
    Arch Pathol Lab Med; 2020 May 15; 144(5):597-601. PubMed ID: 31647316
    [Abstract] [Full Text] [Related]

  • 8. Assessing the impact of the 2018 American Society of Clinical Oncology/College of American Pathologists recommendations on human epidermal growth factor receptor 2 testing by fluorescence in situ hybridization in breast carcinoma.
    Murray C, Flanagan L, D'Arcy C, Gullo G, Quinn CM.
    Virchows Arch; 2020 Mar 15; 476(3):367-372. PubMed ID: 31375912
    [Abstract] [Full Text] [Related]

  • 9. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS, Casas CE, Peng J, Watkins M, Fan L, Chapman J, Ikpatt OF, Gomez C, Zhao W, Reis IM.
    Breast Cancer Res Treat; 2016 Feb 15; 155(3):457-62. PubMed ID: 26895325
    [Abstract] [Full Text] [Related]

  • 10. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
    Bethune GC, Veldhuijzen van Zanten D, MacIntosh RF, Rayson D, Younis T, Thompson K, Barnes PJ.
    Histopathology; 2015 Dec 15; 67(6):880-7. PubMed ID: 25913507
    [Abstract] [Full Text] [Related]

  • 11. Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer.
    Xu B, Shen J, Guo W, Zhao W, Zhuang Y, Wang L.
    Pathol Res Pract; 2019 Feb 15; 215(2):251-255. PubMed ID: 30420102
    [Abstract] [Full Text] [Related]

  • 12. Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features.
    Zare SY, Lin L, Alghamdi AG, Daehne S, Roma AA, Hasteh F, Dell'Aquila M, Fadare O.
    Hum Pathol; 2019 Jan 15; 83():7-13. PubMed ID: 30121371
    [Abstract] [Full Text] [Related]

  • 13. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
    Press MF, Seoane JA, Curtis C, Quinaux E, Guzman R, Sauter G, Eiermann W, Mackey JR, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, Villalobos I, Slamon DJ.
    JAMA Oncol; 2019 Mar 01; 5(3):366-375. PubMed ID: 30520947
    [Abstract] [Full Text] [Related]

  • 14. [Impact of 2013 American Society of Clinical Oncology/College of American Pathologist guidelines on borderline immunostaining results for HER2: a retrospective study on HER2 FISH results in 1 780 cases of invasive breast cancers].
    Xu Y, Bai QM, Yang F, Zhu XL, Lu YM, Zhang J, Yang WT, Zhou XY.
    Zhonghua Bing Li Xue Za Zhi; 2016 Aug 08; 45(8):545-9. PubMed ID: 27510780
    [Abstract] [Full Text] [Related]

  • 15. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS, Bowman AS, Zehir A, Razavi P, Brogi E, Ladanyi M, Arcila ME, Wen HY, Ross DS.
    Histopathology; 2021 Mar 08; 78(4):498-507. PubMed ID: 32841416
    [Abstract] [Full Text] [Related]

  • 16. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
    Varga Z, Noske A.
    PLoS One; 2015 Mar 08; 10(10):e0140652. PubMed ID: 26473483
    [Abstract] [Full Text] [Related]

  • 17. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines.
    Shah MV, Wiktor AE, Meyer RG, Tenner KS, Ballman KV, Green SJ, Sukov WR, Ketterling RP, Perez EA, Jenkins RB.
    J Clin Oncol; 2016 Oct 10; 34(29):3502-3510. PubMed ID: 27458302
    [Abstract] [Full Text] [Related]

  • 18. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results.
    Wang B, Ding W, Sun K, Wang X, Xu L, Teng X.
    Sci Rep; 2019 Nov 13; 9(1):16726. PubMed ID: 31723206
    [Abstract] [Full Text] [Related]

  • 19. Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) gene testing in invasive breast cancers: A single center study.
    Lim TH, Lim AST, Tien SL, Tan PH.
    Ann Diagn Pathol; 2022 Jun 13; 58():151935. PubMed ID: 35313158
    [Abstract] [Full Text] [Related]

  • 20. Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes.
    Blanton KC, Deal AM, Kaiser-Rogers KA, Anders CK, O'Connor SM, Hertel JD, Calhoun BC.
    Ann Diagn Pathol; 2020 Oct 13; 48():151576. PubMed ID: 32805517
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.